Inhibition of PD-L1 using drug MPDL3280A for patients with

2014 ASCO Annual Meeting

Inhibition of PD-L1 using drug MPDL3280A for patients with metastatic urothelial bladder cancer

Listen now

Description

Prof Thomas Powles (Barts Health, London, UK) discusses the use of the drug MPDL3280A to inhibit the protein PD-L1 in patients with metatastatic urothelial bladder cancer.

More Episodes

See all »

Comment: PD-1 targeting MK-3475 gives long-term responses in melanoma

At ASCO 2014, Dr O'Day provides ecancertv with his expert opinion on the findings from a large phase I study of 411 patients with advanced melanoma which showed that the PD-1 targeting antibody MK-3475 yields long-term responses in a high percentage of patients.

Published 07/15/14

2014 ASCO Annual Meeting

Published 07/15/14

ASCO 2014 roundup

ecancer's Prof McVie provides a roundup of the main points of discussion from ASCO 2014.

Published 07/11/14